Compositions and methods for inhibiting EB-1-mediated microtubule stability
AssigneeThe Trustees of Columbia University in the City of New York
InventorsYing Wen, Gregg G. Gundersen
Life of this patent
Estimating the term…
Abstract
This invention provides a recombinant nucleic acid which, when introduced in vivo into a mammalian cell endogenously expressing EB1, inhibits the expression of EB1 therein, thereby reducing the amount of stable microtubules in the cell. This invention further provides related compositions, nucleic acids, cells and methods.
Claims5
A nucleic acid which, when introduced in vivo into a mammalian cell endogenously expressing an EB1 polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:1, inhibits the expression of EB1 in such mammalian cell by greater than 80%, thereby reducing the amount of stable microtubules in the mammalian cell, wherein the nucleic acid is an siRNA comprising SEQ. ID. NO.:7.
A composition comprising (a) a nucleic acid which, when introduced in vivo into a mammalian cell endogenously expressing an EB1 polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:1, inhibits the expression of EB1 in such mammalian cell by greater than 80%, thereby reducing the amount of stable microtubules in the cell, and (b) a pharmaceutically acceptable carrier, wherein the nucleic acid is an siRNA comprising SEQ. ID. NO.:7.
A composition comprising (a) a vector encoding a nucleic acid which, when introduced in vivo into a mammalian cell endogenously expressing an EB1 polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:1, inhibits the expression of EB1 in such mammalian cell by greater than 80%, thereby reducing the amount of stable microtubules in the cell, and (b) a pharmaceutically acceptable carrier, wherein the nucleic acid is an siRNA comprising SEQ. ID. NO.:7.
Dependencies are inferred from the claim text.